Clinical Study of Meplazumab to Treat With Malaria

Summary

This Phase 1 study will be conducted to explore the dose regimen in humans and to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and toxicological effects of meplazumab in healthy subjects, thus providing a new macromolecule antibody drug for the prevention and treatment of P. falciparum infection.

Timeline

Start

2023-03

Primary completion

2023-12

Completion

2024-03

Outcome

Outcome not reported

Stopped: “The same drug has completed the phase I and II clinical trials for COVID-19”

Drugs

Indications